KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Show more
Location: 55 Cambridge Parkway, Cambridge, MA, 02142, United States | Website: https://www.kalvista.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
682.1M
52 Wk Range
$7.30 - $17.28
Previous Close
$13.50
Open
$13.49
Volume
142,736
Day Range
$13.44 - $13.68
Enterprise Value
496.7M
Cash
191.5M
Avg Qtr Burn
-41.8M
Insider Ownership
1.30%
Institutional Own.
-
Qtr Updated
07/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EKTERLY® (sebetralstat) Details Hereditary angioedema | Approved Quarterly sales | |
Sebetralstat (KVD900) (film coated) Details Hereditary angioedema | sNDA Submission | |
KVD824 (plasma kallikrein enzyme inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease | Failed Discontinued | |
KVD001 (IVT) Details Diabetic macular edema, Frontotemporal dementia with C9orf72 mutation, Dementia, Diabetes | Failed Discontinued |